TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Körner, Christian ^a   Riesner, Katarina ^a   Krämer, Benjamin ^a   Eisenhardt, Marianne ^a   Glässner, Andreas ^a   Wolter, Franziska ^a   Berg, Thomas ^b   Müller, Tobias ^c   Sauerbruch, Tilman ^a   Nattermann, Jacob ^a   Spengler, Ulrich ^a   Nischalke, Hans D ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

A683C (RS20576); Apoptosis; C626G (RS20575); Cancer; DR4; HCC; HCV; Polymorphism; Trail receptor I

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; LINKAGE ANALYSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; MUTATOR GENE; SEX DIFFERENCE; TRAIL RECEPTOR 1 GENE; VIRUS LOAD; GENETIC PREDISPOSITION; GENETICS; LIVER TUMOR; MIDDLE AGED; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84862145820     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-85     Document Type: Article

References (21)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997, 26(3 Suppl 1):62S-65S.
2. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005, 17(5):477-483. 10.1097/00042737-200505000-00002, 15827436.
3. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328(25):1797-1801. 10.1056/NEJM199306243282501, 7684822.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485-1491. 10.1200/JCO.2008.20.7753, 2668555, 19224838.
5. Schutte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009, 27(2):80-92. 10.1159/000218339, 19546545.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567. 10.1016/S1473-3099(05)70216-4, 16122679.
7. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010, 31(1):93-112. 10.1016/j.mam.2009.12.002, 19995571.
8. Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol 2010, 22(6):837-844. 10.1016/j.ceb.2010.08.001, 20813513.
9. Chen B, Liu S, Wang XL, Xu W, Li Y, Zhao WH, Wu JQ. TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based meta-analysis. Eur J Cancer 2009, 45(14):2598-2605. 10.1016/j.ejca.2009.06.023, 19643596.
10. Frank B, Hemminki K, Shanmugam KS, Meindl A, Klaes R, Schmutzler RK, Wappenschmidt B, Untch M, Bugert P, Bartram CR, et al. Association of death receptor 4 haplotype 626 C-683C with an increased breast cancer risk. Carcinogenesis 2005, 26(11):1975-1977. 10.1093/carcin/bgi164, 15975957.
11. Frank B, Shanmugam KS, Beckmann L, Hemminki K, Brenner H, Hoffmeister M, Chang-Claude J, Burwinkel B. Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2006, 15(10):2002-2005. 10.1158/1055-9965.EPI-06-0053, 17035413.
12. Ulybina YM, Kuligina E, Mitiushkina NV, Rozanov ME, Ivantsov AO, Ponomariova DN, Togo AV, Levchenko EV, Shutkin VA, Brenister SI, et al. Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett 2009, 278(2):183-191. 10.1016/j.canlet.2009.01.012, 19203830.
13. Wang M, Wang M, Cheng G, Zhang Z, Fu G, Zhang Z. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat Res 2009, 661(1-2):85-92. 10.1016/j.mrfmmm.2008.11.009, 19070628.
14. Lan L, Gorke S, Rau SJ, Zeisel MB, Hildt E, Himmelsbach K, Carvajal-Yepes M, Huber R, Wakita T, Schmitt-Graeff A, et al. Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol 2008, 181(7):4926-4935.
15. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B. Early Changes in Natural Killer Cell Function Indicate Virologic Response to Interferon Therapy for Hepatitis C. Gastroenterology 2011, 141(4):1231-1239. 10.1053/j.gastro.2011.06.069, 21741920.
16. Stegmann KA, Bjorkstrom NK, Veber H, Ciesek S, Riese P, Wiegand J, Hadem J, Suneetha PV, Jaroszewicz J, Wang C, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010, 138(5):1885-1897. 10.1053/j.gastro.2010.01.051, 20334827.
17. Kriegl L, Jung A, Engel J, Jackstadt R, Gerbes AL, Gallmeier E, Reiche JA, Hermeking H, Rizzani A, Bruns CJ, et al. Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma. Clin Cancer Res 2010, 16(22):5529-5538. 10.1158/1078-0432.CCR-09-3403, 20889918.
18. Chen XP, He SQ, Wang HP, Zhao YZ, Zhang WG. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol 2003, 9(11):2433-2440.
19. He S, Chen Y, Chen X, Zhao Y, Wang H, Zhang W, Wang S. Antitumor effects of soluble TRAIL in human hepatocellular carcinoma. J Huazhong Univ Sci Technolog Med Sci 2005, 25(1):51-54. 10.1007/BF02831386, 15934308.
20. Wolf S, Mertens D, Pscherer A, Schroeter P, Winkler D, Grone HJ, Hofele C, Hemminki K, Kumar R, Steineck G, et al. Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006, 118(7):1831-1835. 10.1002/ijc.21502, 16217763.
21. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, Nelson DR, Liu C. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007, 133(5):1649-1659. 10.1053/j.gastro.2007.09.017, 17983809.